$AXSM
Axsome Therapeutics, Inc.

2021 Q2 Form 10-Q Financial Statement

#000156459021042710 Filed on August 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.34M
YoY Change 125.75%
% of Gross Profit
Research & Development $14.50M
YoY Change 37.56%
% of Gross Profit
Depreciation & Amortization $8.080K
YoY Change
% of Gross Profit
Operating Expenses $30.85M
YoY Change 73.51%
Operating Profit
YoY Change
Interest Expense -$1.437M
YoY Change 161.19%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$32.28M
YoY Change 76.13%
Income Tax
% Of Pretax Income
Net Earnings -$32.28M
YoY Change 76.16%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$858.7K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $141.2M
YoY Change -25.95%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $435.8K
YoY Change 335.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $141.7M
YoY Change -25.76%
LONG-TERM ASSETS
Property, Plant & Equipment $1.292M
YoY Change 4148.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $317.4K
YoY Change 126.9%
Total Long-Term Assets $1.610M
YoY Change 845.32%
TOTAL ASSETS
Total Short-Term Assets $141.7M
Total Long-Term Assets $1.610M
Total Assets $143.3M
YoY Change -24.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.61M
YoY Change 24.02%
Accrued Expenses $11.25M
YoY Change 58.47%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.86M
YoY Change -0.6%
LONG-TERM LIABILITIES
Long-Term Debt $48.88M
YoY Change 255.66%
Other Long-Term Liabilities $81.86K
YoY Change
Total Long-Term Liabilities $48.88M
YoY Change 255.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.86M
Total Long-Term Liabilities $48.88M
Total Liabilities $71.83M
YoY Change 95.47%
SHAREHOLDERS EQUITY
Retained Earnings -$340.3M
YoY Change 50.11%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $71.44M
YoY Change
Total Liabilities & Shareholders Equity $143.3M
YoY Change -24.99%

Cashflow Statement

Concept 2021 Q2
OPERATING ACTIVITIES
Net Income -$32.28M
YoY Change 76.16%
Depreciation, Depletion And Amortization $8.080K
YoY Change
Cash From Operating Activities -$25.39M
YoY Change 34.33%
INVESTING ACTIVITIES
Capital Expenditures -$18.87K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$18.87K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.971M
YoY Change -83.94%
NET CHANGE
Cash From Operating Activities -25.39M
Cash From Investing Activities -18.87K
Cash From Financing Activities 1.971M
Net Change In Cash -23.44M
YoY Change 253.5%
FREE CASH FLOW
Cash From Operating Activities -$25.39M
Capital Expenditures -$18.87K
Free Cash Flow -$25.37M
YoY Change 34.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.86
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16344361
us-gaap Operating Expenses
OperatingExpenses
50270291
us-gaap Operating Income Loss
OperatingIncomeLoss
-58691748
us-gaap Operating Income Loss
OperatingIncomeLoss
-50270291
CY2020Q2 us-gaap Investment Income Net
InvestmentIncomeNet
-548158
us-gaap Investment Income Net
InvestmentIncomeNet
-2852431
us-gaap Investment Income Net
InvestmentIncomeNet
-540847
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-32284209
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-18326992
CY2020Q2 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
12074999
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-18326992
axsm Change In Operating Lease Liability
ChangeInOperatingLeaseLiability
-631591
us-gaap Depreciation
Depreciation
18075
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
154243310
us-gaap Depreciation
Depreciation
10960
axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
287431
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
113792909
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
84010
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10000551
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12895167
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-42657363
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29284058
CY2020Q4 us-gaap Cash
Cash
183876453
CY2019Q4 us-gaap Cash
Cash
219966167
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37081064
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
178722389
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2133530
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
629756
CY2020Q1 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
7155337
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-32484146
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
156156866
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4148025
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
190409
CY2020Q2 axsm Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3731097
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1913299
CY2021Q1 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
6115864
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-29259970
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
96293199
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5456242
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
958895
CY2021Q2 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
1096503
CY2021Q2 axsm Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes
AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
84010
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-32284209
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
71436620
us-gaap Profit Loss
ProfitLoss
-61544179
us-gaap Profit Loss
ProfitLoss
-50811138
us-gaap Share Based Compensation
ShareBasedCompensation
9187339
us-gaap Share Based Compensation
ShareBasedCompensation
6281555
axsm Noncash Research And Development Expense
NoncashResearchAndDevelopmentExpense
7155337
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
560752
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
356664
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
530437
axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
-275914
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52609042
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48872
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10759
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48872
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10759
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7212367
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12074999
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2872194
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
820165
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.92%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock‑based compensation expense; the determination of the fair value of the warrants; the accounting for research and development costs; and the recoverability of the Company’s net deferred tax assets and related valuation allowance.</p>
CY2021Q2 us-gaap Cash
Cash
141219090
CY2020Q2 us-gaap Cash
Cash
190682109
us-gaap Interest Paid Net
InterestPaidNet
2312917
us-gaap Interest Paid Net
InterestPaidNet
762501
CY2021Q2 axsm Number Of Late Stage Product Candidates
NumberOfLateStageProductCandidates
5
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-340300000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
141200000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.92%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At June 30, 2021, the majority of the Company’s cash was held by one financial institution and the amount on deposit was in excess of Federal Deposit Insurance Corporation insurance limits. The Company has not recognized any losses from credit risks on such accounts since inception. The Company believes it is not exposed to significant credit risk on cash.</p>
CY2021Q2 axsm Number Of Financial Institutions Holding Deposits
NumberOfFinancialInstitutionsHoldingDeposits
1
us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2195033
CY2020Q4 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
4293522
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3034669
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2870261
CY2021Q2 axsm Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
4551879
CY2020Q4 axsm Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
1155508
CY2021Q2 us-gaap Interest Payable Current
InterestPayableCurrent
381250
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
393958
CY2021Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10162831
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
8713249
CY2021Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1156458
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2300208
CY2020Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
379167
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
758334
CY2021Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
149281
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
292870
CY2020Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
119014
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
238028
axsm Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
646
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1830064
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48882599
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48321848
CY2021Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2021Q2 axsm Debt Instrument Accreted Liability Of Final Payment Fee
DebtInstrumentAccretedLiabilityOfFinalPaymentFee
444783
CY2020Q4 axsm Debt Instrument Accreted Liability Of Final Payment Fee
DebtInstrumentAccretedLiabilityOfFinalPaymentFee
151912
CY2021Q2 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1562184
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
12193153
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
19761468
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
18045379
CY2021Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-32284209
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-18326992
us-gaap Net Income Loss
NetIncomeLoss
-61544179
us-gaap Net Income Loss
NetIncomeLoss
-50811138
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37595069
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37100770
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37512716
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37081064
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.86
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.64
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.37
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4786652
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4166792
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
286923
us-gaap Operating Lease Cost
OperatingLeaseCost
573846
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
575000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
630000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1205000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
34296
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1170704
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y1M6D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
axsm Equity Instrument Voting Rights Per Share
EquityInstrumentVotingRightsPerShare
1
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3725648
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.36
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
955213
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
66.05
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
162503
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
17.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
55727
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
63.58
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4148025
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
87.76
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4461985
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
26.35
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
186299331
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4455816
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
26.38
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
185891183
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2670402
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.19
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
145918708
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
48.74
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
57000000.0
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M18D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
8647
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5456242
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9187339
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6281555
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15541
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.43
axsm Warrants Issued In Period
WarrantsIssuedInPeriod
0
axsm Warrants Issued In Period Weighted Average Exercise Price
WarrantsIssuedInPeriodWeightedAverageExercisePrice
0
axsm Warrants Exercised In Period
WarrantsExercisedInPeriod
0
axsm Warrants Exercised In Period Weighted Average Exercise Price
WarrantsExercisedInPeriodWeightedAverageExercisePrice
0
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15541
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.43

Files In Submission

Name View Source Status
0001564590-21-042710-index-headers.html Edgar Link pending
0001564590-21-042710-index.html Edgar Link pending
0001564590-21-042710.txt Edgar Link pending
0001564590-21-042710-xbrl.zip Edgar Link pending
axsm-10q_20210630.htm Edgar Link pending
axsm-10q_20210630_htm.xml Edgar Link completed
axsm-20210630.xsd Edgar Link pending
axsm-20210630_cal.xml Edgar Link unprocessable
axsm-20210630_def.xml Edgar Link unprocessable
axsm-20210630_lab.xml Edgar Link unprocessable
axsm-20210630_pre.xml Edgar Link unprocessable
axsm-ex311_9.htm Edgar Link pending
axsm-ex312_6.htm Edgar Link pending
axsm-ex321_7.htm Edgar Link pending
axsm-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending